---
title: "CSPC Pharmaceutical Profit Slumps on Sharp Drop in Licence Fee Income"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287717554.md"
description: "CSPC Pharmaceutical Group reported a 7.8% decline in Q1 2026 revenue to RMB6.47 billion, with profit attributable to shareholders dropping 41.8% to RMB860 million, primarily due to a significant decrease in licence fee income. Finished drug sales grew 6.2%, but overall revenue fell 5%. Analysts maintain a Buy rating on the stock with a price target of HK$13.05."
datetime: "2026-05-27T04:38:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287717554.md)
  - [en](https://longbridge.com/en/news/287717554.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287717554.md)
---

# CSPC Pharmaceutical Profit Slumps on Sharp Drop in Licence Fee Income

### Memorial Day Sale – Claim 70% Off TipRanks

-   Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
-   Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.

CSPC Pharmaceutical Group reported first-quarter 2026 revenue of RMB6.47 billion, down 7.8% year on year, with profit attributable to shareholders falling 41.8% to RMB860 million. The sharp profit decline was mainly driven by a steep drop in licence fee income compared with the prior-year period, when the group booked a large upfront payment under exclusive licensing deals.

Excluding licence fees, profit attributable to shareholders decreased a milder 7.3% to RMB736 million, while underlying profit fell 40.3% as investment-related fair value changes and share-based expenses weighed on earnings. Finished drug sales of goods grew 6.2%, supported by strong nervous system and cardiovascular products, but overall finished drug revenue slipped 5% as licence fee income plunged nearly 80%, underscoring the group’s increased earnings sensitivity to one-off licensing revenue.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

**More about CSPC Pharmaceutical Group**

CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company focused on finished drugs, bulk products, and functional foods. Its core portfolio spans therapeutic areas including nervous system, oncology, anti-infectives, cardiovascular, respiratory, and digestive and metabolic diseases, with a growing emphasis on innovative finished drug sales and licensing partnerships.

**Average Trading Volume:** 86,347,378

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$88.46B

For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [562050.CN](https://longbridge.com/en/quote/562050.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)

## Related News & Research

- [Kelun-Biotech's Sac-TMT + Pembrolizumab Improves Survival In Late-Stage China Trial](https://longbridge.com/en/news/287276752.md)
- [CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate](https://longbridge.com/en/news/284559073.md)
- [Coffee Prices Climb as Brazil Rains Delay the Coffee Harvest](https://longbridge.com/en/news/287945375.md)
- [Global Weather Risks Underpin Coffee Prices](https://longbridge.com/en/news/287659130.md)
- [09:30 ETBelk Celebrates Two Decades of Charity Sales Benefitting Local Communities](https://longbridge.com/en/news/287780186.md)